首页> 外文期刊>Cellular and Molecular Life Sciences >Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis
【24h】

Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis

机译:基因治疗方法在肌萎缩性侧索硬化症治疗中的研究进展

获取原文
获取原文并翻译 | 示例
           

摘要

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease of motor neurons that causes progressive muscle weakness, paralysis, and premature death. No effective therapy is available. Research in the motor neuron field continues to grow, and recent breakthroughs have demonstrated the possibility of completely achieving rescue in animal models of spinal muscular atrophy, a genetic motor neuron disease. With adeno-associated virus (AAV) vectors, gene transfer can be achieved with systemic non-invasive injection and minimal toxicity. In the context of this success, we review gene therapy approaches for ALS, considering what has been done and the possible future directions for effective application of the latest generation of vectors for clinical translation. We focus on recent developments in the areas of RNA/antisense-mediated silencing of specific ALS causative genes like superoxide dismutase-1 and other molecular pathogenetic targets, as well as the administration of neuroprotective factors with viral vectors. We argue that gene therapy offers new opportunities to open the path for clinical progress in treating ALS.
机译:肌萎缩性侧索硬化症(ALS)是运动神经元的毁灭性神经退行性疾病,可引起进行性肌肉无力,瘫痪和过早死亡。没有有效的治疗方法。运动神经元领域的研究继续增长,最近的突破表明,在遗传性运动神经元疾病脊柱肌肉萎缩症动物模型中完全实现抢救的可能性。使用腺相关病毒(AAV)载体,可以通过全身无创注射和最小的毒性实现基因转移。在这一成功的背景下,我们回顾了ALS的基因治疗方法,考虑了已完成的工作以及有效应用最新一代载体进行临床翻译的可能的未来方向。我们专注于RNA /反义介导的特定ALS致病基因(如超氧化物歧化酶-1)和其他分子致病靶标的沉默领域的最新进展,以及神经保护因子与病毒载体的管理。我们认为基因治疗提供了新的机会,为临床治疗ALS开辟了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号